The MiniMAX is an anatomical cementless stem engineered to provide the best fit and fill in the metaphyseal femur. First introduced to the market in 2007, it has now reached proven clinical results, obtaining a survival rate at 5 years of 97.5% considering revision for any reason and 100% considering aseptic loosening as endpoint. The implant has been designed to allow easy and straightforward insertion, especially through the AMIS approach.
The MiniMAX in Australia fits into a product range of broadly used primary stems dedicated to AMIS. According to the Australian NJRR report, some Medacta hip implants have been amongst the most used for the past 5 years with a continuous growth. As an example, the Quadra-H is the 2nd most implanted cementless stem in Australia since 2011, with results as good as or even better than the most used total hip replacement systems worldwide. Also, from the latest available, the Quadra-H registered a growth of 27% in this market. The key of this success is the combination between the AMIS approach, dedicated hip implants and unique AMIS education courses that strongly reduced the surgeon’s learning curve. In Australia 95% of Medacta implants are performed through this approach.
Medacta International is the world leader for educating and supporting surgeons starting with anterior approach. Reference Centers, located throughout the world, provide the necessary AMIS educational experience and Medacta offers continuous support for surgeons, as well as constantly improving and developing the industries most specialised instrumentation platform. The MiniMAX stem is another step to further reinforce Medacta’s leading position in anterior approach development.
MiniMAX is not FDA cleared.
 Dr. P.G. Vasina, Dr. R. Rossi, Dr. P. Palumbi, MiniMAX anatomical stem 5 years clinical outcomes.